US · Healthcare · Biotechnology
EPS came in at 0.04 against a street estimate of -0.04 — a beat of 200.0%.
Analysts rate Vericel Corp Ord a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $60.57.
CONFIDENT VCEL crushed Q2 with $77.5M revenue (+22% YoY), record MACI at $65.5M (+23%), and initiated $200M buyback. Full-year guidance raised to $330–340M. Strong cash generation ($14.3M FCF) and margin expansion on track. Q2 2026 U.S. driving all current growth; U.K. beachhead expected late 2026/early 2027 with light commercial footprint. Analysts probed MACI's 2-year acceleration, pricing durability, and H2 decel. Management attributed gains to sales force ramp and Arthro, affirmed pricing power vs. gene/cell therapies, and defended H2 guidance as prudent while noting internal expectations exceed guide. 2026-07-30…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.16% |
| State Street Corp | 6.16% |
| Congress Asset Management Company, LLP | 5.70% |
| Vanguard Capital Management, LLC | 4.36% |
| Conestoga Capital Advisors, LLC | 4.07% |
| William Blair Investment Management, LLC | 3.89% |
| BNP Paribas Investment Partners SA | 3.37% |
| GW&K Investment Management, LLC | 3.16% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 VERICEL CORPORATION - Q2 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Q2 2026 Revenue: $77.5 million (vs. $63.2 million in Q2 2025) — +22.5% | 2026-07-30 |
| Results announced · Q3 2026 VERICEL CORPORATION Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenue: $77.5 million in Q2 2026, up 22% year-over-year from $63.2 million in | 2026-07-30 |
| Charter / bylaws change · Q2 2026 VERICEL CORPORATION (VCEL) - FORM 8-K SUMMARY OTHER NOTABLE POINTS • Corporate headquarters relocation: Company moved its principal executive office | 2026-05-18 |
| Quarterly report · Q1 2026 VERICEL CORPORATION - Q1 2026 SUMMARY HEADLINE NUMBERS • Total revenue Q1 2026: $68.4 million (Q1 2025: $52.6 million) — 30% increase year-over-year | 2026-05-07 |
| Results announced · Q2 2026 VERICEL CORPORATION Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenue: $68.4 million, up 30% year-over-year (Q1 2025: $52.6 million) • MACI | 2026-05-07 |
| Shareholder vote results · Q2 2026 VERICEL CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held April 29, 2026 • Total votes cast for director elections: | 2026-05-01 |
| Proxy statement · Q2 2026 VERICEL CORPORATION PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Vote 1 (Page 20): Elect seven (7) directors for one-year terms expiring at 2027 | 2026-03-19 |
| Annual report FY2025 VERICEL CORPORATION – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market capitalization: approximately $2.1 billion (non-affiliate holdings | 2026-02-26 |
Readable in the app.
| Announcement | Date |
|---|---|
| Raises full-year financial guidance and announces share repurchase program Vericel Corporation reported strong second quarter 2026 financial results and took two major positive actions. First, the company raised its full-year 2026 financial guidance, indicating bet | 2026-07-30 |
| Raises full-year financial guidance following first quarter results Vericel Corporation reported first quarter 2026 financial results and raised its full-year financial guidance. This announcement indicates the company performed better than expected in Q1 20 | 2026-05-07 |
| Preliminary full-year 2025 revenue, net income, and margin estimates disclosed Vericel Corporation issued preliminary and unaudited 2025 financial results ahead of presenting at the J.P. Morgan Healthcare Conference on January 14, 2026. The filing includes estimates fo | 2026-01-13 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Vericel Corp Ord — free to start.
Google PlayApp StoreData updated 2026-09-18.